P-076 - A PHASE 1 STUDY EVALUATING THE BIOEQUIVALENCE BETWEEN HLX11, A CHINA-MANUFACTURED PERTUZUMAB BIOSIMILAR CANDIDATE, AND PERTUZUMAB FROM THREE DIFFERENT SOURCES IN HEALTHY CHINESE MALE SUBJECTS.
R. Zhou1, W. Hu1, L. Zheng1, Y. Liu1, Q. Zhang1, J. Yang1, G. Sun2, L. Zhou2, W. Kang2, J. Zhu2; 1The Second Hospital of Anhui Medical University, Hefei, China, 2Shanghai Henlius Biotech, Inc., Shanghai, China.
.jpg "Wei Hu, MD, PhD photo")
.png)